Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Youngkyoung Lim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Melanoma, Nevus, Pigmented, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Studies on the interaction between tumour‐infiltrating immune cells (TIICs) and tumour cells in melanoma arising from congenital melanocytic nevus (CMN) are lacking.
Objective
The aim of this study was to determine the intratumoral immune landscape of TIICs and tumour cells during invasion and metastasis.
Methods
Tissue specimens were obtained from patients with melanoma originating from CMN. Differential gene expression in melanoma cells and TIICs during invasion and metastasis was determined using spatial transcriptomics.
Results
As invasion depth increased, the expression of LGALS3 , known to induce tumour‐driven immunosuppression, increased in melanoma cells. In T cells, the expression of genes that inhibit T‐cell activation increased with increasing invasion depth. In macrophages, the expression of genes related to the anti‐inflammatory M2 phenotype was upregulated with increasing invasion depth. Compared to primary tumour cells, melanoma cells in metastatic lesions showed upregulated expression of genes associated with cancer immune evasion, including AXL and EPHA2 , which impede T‐cell recruitment, and BST2 , associated with M2 polarization. Furthermore, T cells showed increased expression of genes related to immunosuppression, and macrophages exhibited increased expression of genes associated with the M2 phenotype.
Conclusions
The interaction between melanomas arising from CMN and TIICs may be important for tumour progression and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea.
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
- Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
ORCID-Profile: Youngkyoung Lim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lim, Y., Cho, B. K., Kang, S. J., Jeong, S., Kim, H. J., Baek, J., Moon, J. H., Lee, C., Park, C. S., Mun, J. H., Won, C. H., & Park, C. G. (2024). Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19881
Vancouver
Lim Y, Cho BK, Kang SJ, Jeong S, Kim HJ, Baek J, et al. Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19881
BibTeX
@article{Lim2024,
author = {Lim, Youngkyoung and Cho, Beom Keun and Kang, Seong-Jun and Jeong, Soyoung and Kim, Hyun Je and Baek, Jiyoon and Moon, Ji Hwan and Lee, Cheol and Park, Chan-Sik and Mun, Je-Ho and Won, Chong Hyun and Park, Chung-Gyu},
title = {Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19881}
}
EUVIMED